Proliferation and AKT Activity Biomarker Analyses After Capivasertib (AZD5363) Treatment of Patients With ER+ Invasive Breast Cancer (STAKT)
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-19-3053
Full Text
Open PDFAbstract
Available in full text
Date
December 13, 2019
Authors
Publisher
American Association for Cancer Research (AACR)